FDA-approved drugs such as ivosidenib and enasidenib, which target IDH1 and IDH2 respectively, have shown clinical efficacy in treating IDH-mutant AML, glioma, and cholangiocarcinoma, both as monotherapies and in combination therapies (88, 92–95). Here, IDH1 is linked to central nervous system cancer.